Dr. Timothy Yap
Claim this profileM D Anderson Cancer Center
Expert in Tumors
Expert in Solid Tumors
30 reported clinical trials
48 drugs studied
About Timothy Yap
Education:
- Holds an MD (Doctor of Medicine).
- Earned a PhD (Doctor of Philosophy).
Experience:
- Serves as a Medical Oncology Physician-Scientist and Tenure-Track Associate Professor at the University of Texas MD Anderson Cancer Center, contributing to the Departments of Investigational Cancer Therapeutics and Thoracic/Head & Neck Medical Oncology.
- Acts as the Medical Director of the Institute for Applied Cancer Science and Associate Director of Translational Research in the Institute for Personalized Cancer Therapy at MDACC.
- Previously held the position of National Institute for Health Research Biomedical Research Centre Clinician-Scientist in Medical Oncology at the Royal Marsden Hospital and The Institute of Cancer Research in London, England.
Area of expertise
1Tumors
Global LeaderStage IV
BRCA1 positive
BRCA2 positive
2Solid Tumors
Global LeaderStage IV
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Timothy Yap is currently running
Adagrasib + Olaparib
for Solid Tumors
This trial is testing a combination of two drugs, adagrasib and olaparib, in patients with advanced solid tumors that have specific genetic mutations. The goal is to find a safe dose and see if the combination can effectively block cancer growth and prevent cancer cells from repairing themselves. Olaparib has shown activity in various cancers, particularly those with certain genetic mutations.
Recruiting1 award Phase 112 criteria
SW-682
for Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Recruiting1 award Phase 16 criteria
More about Timothy Yap
Clinical Trial Related1 year of experience running clinical trials · Led 30 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Timothy Yap has experience with
- Olaparib
- Niraparib
- Nivolumab
- Talazoparib
- Copanlisib
- Tislelizumab
Breakdown of trials Timothy Yap has run
Tumors
Solid Tumors
Cancer
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Timothy Yap specialize in?
Timothy Yap focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are BRCA1 positive.
Is Timothy Yap currently recruiting for clinical trials?
Yes, Timothy Yap is currently recruiting for 13 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Timothy Yap has studied deeply?
Yes, Timothy Yap has studied treatments such as Olaparib, Niraparib, Nivolumab.
What is the best way to schedule an appointment with Timothy Yap?
Apply for one of the trials that Timothy Yap is conducting.
What is the office address of Timothy Yap?
The office of Timothy Yap is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.